Abiopharma

🔍 Lippis Daniel J. (Executive)

Company: Edwards Lifesciences Corp (EW)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Acquired 619 shares of Common Stock at $72.68 per share (Direct)
  Date: 2026-06-30 | Code: M | equity_swap_involved: 0 | shares_owned_after: 41,029.91 | transaction_form_type: 4 | Footnotes: F1
• Sold 619 shares of Common Stock at $91.4002 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 40,410.91 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 619 shares of Employee Stock Option (Right to Acquire) at $72.68 per share (Derivative)
  Date: 2026-06-30 | Code: M | Expires: 2027-05-06 | Exercise: 2021-05-07 | equity_swap_involved: 0 | shares_owned_after: 5,571.00 | transaction_form_type: 4

Footnotes:

• F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.
• F2: This transaction was executed in multiple trades at prices ranging from $91.185 to $91.650. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
• REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.